Nemkova S A, Semenov D V, Petrova E A, Zavadenko N N, Vozvyshaeva M Yu
Pirogov Russian National Research Medical University, Moscow, Russia.
Russian State Social University, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(9):51-57. doi: 10.17116/jnevro202112109151.
The aim of the observational program was to study the effect of the use of the drug recognan (citicoline) on the state of higher mental functions (memory, attention, visual-motor coordination, dynamic praxis,verbal thinking and imagination) in patients with mild cognitive impairment.
A survey of 54 subjects (16 of them male and 38 female) aged 18-50 years (average age 28.5±10.5 years) was conducted with a diagnosis of «Mild cognitive impairment» («F06.7»). The group was randomized into 2 subgroups: the main subgroup (26 people) received oral therapy with the drug Recognan, for 30 days, with the daily dosage of the drug being 500 mg. In the control group (28 people), nootropic drug therapy was not performed. Standard psychometric techniques were used to study higher mental functions. All subjects were examined three times (initially, in the middle of the study - on day 15, at the end of the study - on day 30).
After 2 weeks of treatment with recognan, there was an improvement in concentration in 81.9%, memory in 50% (=0.008), verbal imagination productivity in 68.2% (=0.015), counting functions in 60% (=0.015), visual-motor coordination and dynamic praxis - in 86.4% (=0.003), increased speed and efficiency of mental work (=0.001). After a 30-day course of treatment with recognan, there was an improvement in memory in 58.3% of patients (=0.007), an increase in concentration in 64%, an improvement in counting functions in 64.3% (=0.011), verbal imagination productivity in 63.3%, visual-motor coordination and dynamic praxis in 86.4% (=0.007), speed and efficiency of mental work (=0.006), which indicates a complex positive effect of recognan on higher mental functions in patients with mild cognitive impairment cognitive impairment.
该观察项目旨在研究使用药物瑞可南（胞磷胆碱）对轻度认知障碍患者高级心理功能（记忆、注意力、视运动协调、动态运用、言语思维和想象力）状态的影响。
对54名年龄在18 - 50岁（平均年龄28.5±10.5岁）、诊断为“轻度认知障碍”（“F06.7”）的受试者进行了调查。该组被随机分为2个亚组：主要亚组（26人）接受瑞可南药物口服治疗30天，药物每日剂量为500毫克。对照组（28人）未进行促智药物治疗。使用标准心理测量技术研究高级心理功能。所有受试者接受了三次检查（最初、研究中期 - 第15天、研究结束时 - 第30天）。
使用瑞可南治疗2周后，81.9%的患者注意力得到改善，50%的患者记忆力得到改善（=0.008），68.2%的患者言语想象力生产力得到改善（=0.015），60%的患者计数功能得到改善（=0.015），86.4%的患者视运动协调和动态运用得到改善（=0.003），心理工作速度和效率提高（=0.001）。经过30天的瑞可南治疗疗程后，58.3%的患者记忆力得到改善（=0.007），64%的患者注意力增强，64.3%的患者计数功能得到改善（=0.011），63.3%的患者言语想象力生产力得到改善，86.4%的患者视运动协调和动态运用得到改善（=0.007），心理工作速度和效率提高（=0.006），这表明瑞可南对轻度认知障碍患者的高级心理功能具有综合积极影响。
